Runben Biotechnology (603193) 中邮证券·2025-04-27 06:47Investment Rating - The investment rating for the company is "Buy" and is maintained [2] Core Views - The company reported a revenue of 1.32 billion yuan in 2024, representing a year-on-year increase of 27.6%, and a net profit attributable to shareholders of 300 million yuan, up 32.8% year-on-year [5] - The company is expected to maintain strong growth in the baby care segment and continue launching new products to capture market share [8] Company Overview - Latest closing price: 35.58 yuan - Total shares: 4.05 billion, circulating shares: 1.03 billion - Total market capitalization: 14.4 billion yuan, circulating market capitalization: 3.7 billion yuan - 52-week high/low: 36.53/16.13 yuan - Debt-to-asset ratio: 6.3% - Price-to-earnings ratio: 48.08 [4] Financial Performance - In Q4 2024, the company achieved revenue and net profit of 280 million yuan and 40 million yuan, respectively, with year-on-year growth of 34% and a decline of 13% [5] - In Q1 2025, revenue and net profit were 240 million yuan and 44 million yuan, respectively, with year-on-year growth of 44% and 25% [5] - The gross profit margin for 2024 increased by 1.8 percentage points to 58.2% [7] - The company expects net profits of 390 million yuan, 500 million yuan, and 604 million yuan for 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 36 times, 29 times, and 24 times [8][11] Revenue Breakdown - In 2024, revenue from mosquito repellent, baby care, and essential oils was 440 million yuan, 690 million yuan, and 160 million yuan, respectively, with year-on-year growth of 35%, 32%, and 8% [6] - For Q1 2025, revenue growth rates for mosquito repellent, baby care, and essential oils were 66%, 11%, and -6%, respectively [6] - Online direct sales and non-platform distributors showed strong performance, with revenue growth of 24.8% and 39.6% in 2024 [6]